Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion.

Tofeeq Ur-Rehman | Anatoly Slepenkin | Hencelyn Chu | Anders Blomgren | Markus K Dahlgren | Caroline E Zetterström | Ellena M Peterson | Mikael Elofsson | Asa Gylfe
The Journal of antibiotics | 2012

Salicylidene acylhydrazides belong to a class of compounds shown to inhibit bacterial type III secretion (T3S) in pathogenic Gram-negative bacteria. This class of compounds also inhibits growth and replication of Chlamydiae, strict intracellular bacteria that possess a T3S system. In this study a library of 58 salicylidene acylhydrazides was screened to identify inhibitors of Chlamydia growth. Compounds inhibiting growth of both Chlamydia trachomatis and Chlamydophila pneumoniae were tested for cell toxicity and seven compounds were selected for preliminary pharmacokinetic analysis in mice using cassette dosing. Two compounds, ME0177 and ME0192, were further investigated by individual pharmacokinetic analysis. Compound ME0177 had a relatively high peak plasma concentration (C(max)) and area under curve and therefore may be considered for systemic treatment of Chlamydia infections. The other compound, ME0192, had poor pharmacokinetic properties but the highest anti-chlamydial activity in vitro and therefore was tested for topical treatment in a mouse vaginal infection model. ME0192 administered vaginally significantly reduced the infectious burden of C. trachomatis and the number of infected mice.

Pubmed ID: 22669447

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIAID NIH HHS, United States
    Id: AI-71104
  • Agency: NIAID NIH HHS, United States
    Id: R01 AI071104
  • Agency: NIAID NIH HHS, United States
    Id: R33 AI079775
  • Agency: NIAID NIH HHS, United States
    Id: R21 AI079775
  • Agency: NIAID NIH HHS, United States
    Id: AI-79775

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


SigmaStat (tool)

RRID:SCR_010285

Software tool for data graphing and analysis by Systat Software, Inc.

View all literature mentions

HEp-2 (tool)

RRID:CVCL_1906

Cell line HEp-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

HeLa (tool)

RRID:CVCL_0030

Cell line HeLa is a Cancer cell line with a species of origin Homo sapiens

View all literature mentions

HeLa 229 (tool)

RRID:CVCL_1276

Cell line HeLa 229 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

C3H/HeJ (tool)

RRID:IMSR_JAX:000659

Mus musculus with name C3H/HeJ from IMSR.

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions